\-\ Texto\\:\\ \ \(0\)\
\-\ noncontributory\ \(52\)\
\-\ unknown\ \(157\)\
\-\ nodular\\ or\\ plaque\\-like\\ deposits\\ intimately\\ related\\ to\\ the\\ conus\\ and\\ cauda\\ equina\\.\ \(0\)\
\-\ drop\\ metastases\\ from\\ previously\\ resected\\ subependymoma\\.\ \(0\)\
\-\ given\\ patient\\â\\€\\™s\\ history\\,\\ the\\ diagnosis\\ of\\ exclusion\\ is\\ metastatic\\ disease\\ from\\ the\\ patients\\ known\\ primary\\.\\ \\ however\\,\\ one\\ should\\ consider\\ metastatic\\ disease\\ from\\ other\\ malignancies\\ as\\ well\\.\ \(0\)\
\-\ 58\\ male\\ with\\ a\\ history\\ of\\ a\\ previously\\ resected\\ subependymoma\\ at\\ the\\ level\\ of\\ the\\ foramen\\ of\\ monroe\\ who\\ was\\ undergoing\\ routine\\ screening\\.\ \(0\)\
\-\ this\\ case\\ demonstrates\\ the\\ nodular\\ appearance\\ of\\ csf\\ seeding\\ of\\ malignancies\\.\\ \\ without\\ the\\ post\\ gadolinium\\ images\\ the\\ diagnosis\\ would\\ potentially\\ not\\ be\\ apparent\\,\\ but\\ with\\ contrast\\ the\\ dramatic\\ enhancement\\ is\\ quite\\ visible\\.\\ \\ as\\ there\\ has\\ not\\ been\\ any\\ recent\\ imaging\\ of\\ the\\ patient\\,\\ his\\ outcome\\ is\\ unknown\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ subependymoma\\:\\ 0\\.09296814925733411\ \(0\)\
\-\ malignancies\\:\\ 0\\.08381880913815422\ \(0\)\
\-\ resected\\:\\ 0\\.06508539915839887\ \(0\)\
\-\ intimately\\:\\ 0\\.05936081642537222\ \(0\)\
\-\ plaque\\-like\\:\\ 0\\.05543138855024922\ \(0\)\
\-\ monroe\\:\\ 0\\.05543138855024922\ \(0\)\
\-\ previously\\:\\ 0\\.055227257696204575\ \(0\)\
\-\ nodular\\:\\ 0\\.05514476626326018\ \(0\)\
\-\ unknown\\:\\ 0\\.05130583847114626\ \(0\)\
\-\ seeding\\:\\ 0\\.049366331932062524\ \(0\)\
\-\ cauda\\:\\ 0\\.044034430543139866\ \(0\)\
\-\ equina\\:\\ 0\\.044034430543139866\ \(0\)\
\-\ exclusion\\:\\ 0\\.044034430543139866\ \(0\)\
\-\ deposits\\:\\ 0\\.042459088907401306\ \(0\)\
\-\ dramatic\\:\\ 0\\.042459088907401306\ \(0\)\
\-\ drop\\:\\ 0\\.04046284894213142\ \(0\)\
\-\ conus\\:\\ 0\\.039630436752591175\ \(0\)\
\-\ quite\\:\\ 0\\.039630436752591175\ \(0\)\
\-\ outcome\\:\\ 0\\.03924574120970916\ \(0\)\
\-\ potentially\\:\\ 0\\.0385296610322783\ \(0\)\
\-\ 58\\:\\ 0\\.03631672201341845\ \(0\)\
\-\ consider\\:\\ 0\\.03570100887746816\ \(0\)\
\-\ metastatic\\:\\ 0\\.03309399082486293\ \(0\)\
\-\ undergoing\\:\\ 0\\.03223496623601713\ \(0\)\
\-\ noncontributory\\:\\ 0\\.03151553502054926\ \(0\)\
\-\ foramen\\:\\ 0\\.031379384427476946\ \(0\)\
\-\ gadolinium\\:\\ 0\\.03117957299360571\ \(0\)\
\-\ visible\\:\\ 0\\.031114106150006413\ \(0\)\
\-\ diagnosis\\:\\ 0\\.030187989704314154\ \(0\)\
\-\ from\\:\\ 0\\.02922543953432798\ \(0\)\
\-\ apparent\\:\\ 0\\.029065890935022074\ \(0\)\
\-\ metastases\\:\\ 0\\.02808255730802296\ \(0\)\
\-\ screening\\:\\ 0\\.0280387263763719\ \(0\)\
\-\ csf\\:\\ 0\\.02744995655235394\ \(0\)\
\-\ related\\:\\ 0\\.027132703025168948\ \(0\)\
\-\ routine\\:\\ 0\\.026357282262692287\ \(0\)\
\-\ would\\:\\ 0\\.023392052910939154\ \(0\)\
\-\ given\\:\\ 0\\.022533956865510327\ \(0\)\
\-\ recent\\:\\ 0\\.02209783883722921\ \(0\)\
\-\ disease\\:\\ 0\\.02148826986485699\ \(0\)\
\-\ should\\:\\ 0\\.020955450322221538\ \(0\)\
\-\ known\\:\\ 0\\.020800392957414\ \(0\)\
\-\ post\\:\\ 0\\.02069873102363303\ \(0\)\
\-\ any\\:\\ 0\\.02069873102363303\ \(0\)\
\-\ as\\:\\ 0\\.019885807782986584\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.01964635953573428\ \(0\)\
\-\ primary\\:\\ 0\\.019472186637659206\ \(0\)\
\-\ not\\:\\ 0\\.018997210334491314\ \(0\)\
\-\ level\\:\\ 0\\.018945300212668707\ \(0\)\
\-\ his\\:\\ 0\\.018945300212668707\ \(0\)\
\-\ s\\:\\ 0\\.018852058977804516\ \(0\)\
\-\ appearance\\:\\ 0\\.018799281359497242\ \(0\)\
\-\ however\\:\\ 0\\.018302831196900543\ \(0\)\
\-\ history\\:\\ 0\\.018157146733955132\ \(0\)\
\-\ been\\:\\ 0\\.017883037611261473\ \(0\)\
\-\ one\\:\\ 0\\.0178133183331588\ \(0\)\
\-\ enhancement\\:\\ 0\\.017619144354792584\ \(0\)\
\-\ who\\:\\ 0\\.017138218531859248\ \(0\)\
\-\ patients\\:\\ 0\\.017012112302815584\ \(0\)\
\-\ without\\:\\ 0\\.015477024356601234\ \(0\)\
\-\ imaging\\:\\ 0\\.015400567880427714\ \(0\)\
\-\ other\\:\\ 0\\.015151065759249606\ \(0\)\
\-\ well\\:\\ 0\\.01486985348437424\ \(0\)\
\-\ contrast\\:\\ 0\\.01471365912929158\ \(0\)\
\-\ case\\:\\ 0\\.014380803329748237\ \(0\)\
\-\ demonstrates\\:\\ 0\\.014358624628101432\ \(0\)\
\-\ but\\:\\ 0\\.014019256161796443\ \(0\)\
\-\ patient\\:\\ 0\\.013178337398713661\ \(0\)\
\-\ is\\:\\ 0\\.012975941039647516\ \(0\)\
\-\ images\\:\\ 0\\.012609722245764263\ \(0\)\
\-\ has\\:\\ 0\\.012343845926879062\ \(0\)\
\-\ male\\:\\ 0\\.011886196445288256\ \(0\)\
\-\ the\\:\\ 0\\.010634560361817369\ \(0\)\
\-\ be\\:\\ 0\\.010136590179568685\ \(0\)\
\-\ there\\:\\ 0\\.00978242735742299\ \(0\)\
\-\ at\\:\\ 0\\.008905870406397178\ \(0\)\
\-\ \\,\\:\\ 0\\.008329540477454997\ \(0\)\
\-\ or\\:\\ 0\\.007704021145874674\ \(0\)\
\-\ was\\:\\ 0\\.00760213478625913\ \(0\)\
\-\ this\\:\\ 0\\.007393363179339485\ \(0\)\
\-\ of\\:\\ 0\\.0062732815814301466\ \(0\)\
\-\ a\\:\\ 0\\.006101535412593866\ \(0\)\
\-\ to\\:\\ 0\\.003285139295715279\ \(0\)\
\-\ \\.\\:\\ 0\\.002184586836759771\ \(0\)\
\-\ with\\:\\ 0\\.0018000642475367653\ \(0\)\
\-\ and\\:\\ 0\\.0013846846594786036\ \(0\)\
